Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 12, 2010, Pages 2505-2513

  Siikala, Emilia ^a,b,c   Rautemaa, Riina ^a,c,d   Richardson, Malcolm ^e   Saxen, Harri ^f   Bowyer, Paul ^d   Sanglard, Dominique ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Candidosis; CDR1; CDR2; Chronic oral candidosis; CMC; Fluconazole; Resistance; TAC1

Indexed keywords

CDR1 PROTEIN; CDR2 PROTEIN; ERG11 PROTEIN; FLUCONAZOLE; FUNGAL PROTEIN; ITRACONAZOLE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PYRROLE DERIVATIVE; TAC1 PROTEIN; UNCLASSIFIED DRUG;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CANDIDA ALBICANS; CLINICAL ARTICLE; CONTROLLED STUDY; FINLAND; FUNGAL COLONIZATION; FUNGAL GENE; FUNGAL STRAIN; FUNGUS ISOLATION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; MULTILOCUS SEQUENCE TYPING; NONHUMAN; NORTHERN BLOTTING; POINT MUTATION; WESTERN BLOTTING;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS, ORAL; CHRONIC DISEASE; DRUG RESISTANCE, FUNGAL; FINLAND; FLUCONAZOLE; FUNGAL PROTEINS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYENDOCRINOPATHIES, AUTOIMMUNE;

EID: 78149487663     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq354     Document Type: Article

References (38)

1. Aaltonen J, Björses P, Sandkuijl L et al. An autosomal locus causing autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet 1994; 8: 83-7.
2. Zuklys S, Balciunaite G, Agarwal A et al. Normal thymic architecture and negative selection are associated with Aire expression, the gene defective in the autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J Immunol 2000; 165: 1976-83.
3. Husebye ES, Perheentupa J, Rautemaa R et al. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 2009; 265: 514-29.
4. Lilic D, Calvert JE, Cant AJ et al. Chronic mucocutaneous candidiasis. II. Class and subclass of specific antibody responses in vivo and in vitro. Clin Exp Immunol 1996; 105: 213-9.
5. Peterson P, Perheentupa J, Krohn KJE. Detection of candidal antigens in autoimmune polyglandular syndrome type I. Clin Diagn Lab Immunol 1996; 3: 290-4.
6. Björses P, Aaltonen J, Horelli-Kuitunen N et al. Gene defect behind APECED: a new clue to autoimmunity. Hum Mol Genet 1998; 7: 1547-53.
7. Kekäläinen E, Tuovinen H, Joensuu J et al. A defect of regulatory T cells in patients with autoimmune polyendocrinpathy-candidiasis-ectodermal dystrophy. J Immunol 2007; 15: 1208-15.
8. Rautemaa R, Richardson M, Pfaller M et al. Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. J Antimicrob Chemother 2007; 60: 889-92.
9. Rautemaa R, Richardson M, Pfaller M et al. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn Microbiol Infect Dis 2008; 62: 182-5.
10. Siikala E, Richardson M, Pfaller MA et al. Candida albicans isolates from APECED patients show decreased susceptibility to miconazole. Int J Antimicrob Agents 2009; 34: 607-9.
11. Li SY, Yang YL, Chen KW et al. Molecular epidemiology of long-term colonization of Candida albicans strains from HIV-infected patients. Epidemiol Infect 2006; 134: 265-9.
12. White TC, Holleman S, Dy F et al. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46: 1704-13.
13. Sanglard D, Kuchler K, Ischer F et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-86.
14. Goldman GH, da Silva Ferreira ME, dos Reis Marques E et al. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 2004; 50: 25-32.
15. Kelly SL, Lamb DC, Loeffler J et al. The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun 1999; 262: 174-9.
16. Sanglard D, Ischer F, Calabrese D et al. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist Updat 1998; 1: 255-65.
17. Morschhäuser J, Barker KS, Liu TT et al. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 2007; 3: e164.
18. Tsao S, Rahkhoodaee F, Raymond M. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob Agents Chemother 2009; 53: 1344-52.
19. Coste AT, Karababa M, Ischer F et al. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004; 3: 1639-52.
20. Rustad TR, Stevens DA, Pfaller MA et al. Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology 2002; 148: 1061-72.
21. Basma R, Barada G, Ojaimi N et al. Susceptibility of Candida albicans to common and novel antifungal drugs, and relationship between the mating type locus and resistance, in Lebanese hospital isolates. Mycoses 2009; 52: 141-8.
22. Dunkel N, Blass J, Rogers PD et al. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole resistant Candida albicans strains. Mol Microbiol 2008; 6: 827-40.
23. Arendrup M, Lundgren B, Jensen IM et al. Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates. J Antimicrob Chemother 2001; 47: 521-6.
24. Bougnoux ME, Morand S, d'Enfert C. Usefulness of multilocus sequence typing for characterization of clinical isolates of Candida albicans. J Clin Microbiol 2002; 40: 1290-7.
25. Bougnoux ME, Tavanti A, Bouchier C et al. Collaborative consensus for optimized multilocus sequence typing of Candida albicans. J Clin Microbiol 2003; 41: 5265-6.
26. Sanglard D, Ischer F, Calabrese D et al. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999; 43: 2753-65.
27. Odds FC, Davidson AD, Jacobsen MD et al. Candida albicans strain maintenance, replacement, and microvariation demonstrated by multilocus sequence typing. J Clin Microbiol 2006; 44: 3647-58.
28. Coste A, Selmecki A, Forche A et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell 2007; 6: 1889-904.
29. Rognon B, Kozovska Z, Coste AT et al. Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. Microbiology 2006; 152: 3701-22.
30. Sanglard D, Ischer F, Koymans L et al. Amino acid substitutions in the cytochrome P-450 lanosterol 14a-demethylase (CYP51A1) from azole resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 1998; 42: 241-53.
31. Coste AT, Crittin J, Bauser C et al. Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot Cell 2009; 8: 1250-67.
32. Clinical and Laboratory Standards Institute. Reference Method For Broth Dilution Antifungal Susceptibility Testing of Yeasts-Second Edition. Approved Standard M27-A2. CLSI, Wayne, PA, 2002.
33. Perea S, López-Ribot JL, Kirkpatrick WR et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-84.
34. Rautemaa R, Richardson M, Pfaller M et al. Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole. Scand J Infect Dis 2008; 40: 904-7.
35. Morschhäuser J. Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 2010; 47: 94-106.
36. Löffler J, Kelly SL, Hebart H et al. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett 1997; 15: 1263-8.
37. Marichal P, Koymans L, Willemsens S et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999; 145: 2701-13.
38. Park S, Perlin DS. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb Drug Resist 2005; 11: 232-8.